The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
At launch of updated pediatric gastroenterology textbook, Union Minister says technology must strengthen not substitute core medical learning
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
